COMBINED THERAPY OF TYPE 2 DIABETES MELLITUS


Cite item

Full Text

Abstract

The article discusses the problems associated with type 2 diabetes mellitus (DM2). Data for medical and social consequences of DM, etiology and factors contributing to the development of this disease are presented. Treatment algorithm of DM2, adopted by the EASD and ADA in 2008 is considered. This algorithm provides effect on the basic components of pathogenesis of DM2, such as insulin resistance and dysfunction of β-cells of the pancreas and contributes to effective glycemic control.

References

  1. Алгоритмы специализированной медицинской помощи больным сахарным диабетом // Под редакцией Дедова И.И., Шестаковой М.В. М., 2009.
  2. Дедов И.И., Шестакова М.В. Сахарный диабет. Руководство для врачей. М., 2003.
  3. Abdul-Ghani M, Tripathy D, DeFronzo RA. Contributions of β-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 2006;29:1130-39.
  4. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999;131:281-303.
  5. Klip A, Leiter LA. Cellular mechanism of action of metformin. Diabetes Care 1990;13(6):696-704.
  6. McFarlane SI, Banerij M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001;86:713-18.
  7. Mooradian AD, Thurman JE. Drug therapy of postprandial hyperglycemia. Drugs 1999;57:1929.
  8. Patane G, Piro S, Rabuazzo AM., et al. Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct metformin effect on pancreatic beta-cells. Diabetes 2001;49(5):735-40.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2011 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies